Following the recent approval by The Medicines and Healthcare products Regulatory Agency (MHRA), we are delighted to announce the launch of two novel strengths of Aripiprazole in the UK.
These new strengths are being introduced to support greater precision and flexibility in the initiation, titration, and maintenance in the following patient groups:
- Treatment of schizophrenia in adults and in adolescents aged 15 years and older
- Treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment
- Treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.